IRC
ALXN

Investors Research Corp’s Alexion Pharmaceuticals ALXN Stock Holding History

Investors Research Corp’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-304
Closed -$56K – 1069
2021
Q2 		$56K Hold
304
– – 0.02% 505
2021
Q1 		$46K Hold
304
– – 0.02% 530
2020
Q4 		$47K Hold
304
– – 0.02% 558
2020
Q3 		$35K Hold
304
– – 0.02% 575
2020
Q2 		$34K Hold
304
– – 0.02% 578
2020
Q1 		$27K Hold
304
– – 0.02% 556
2019
Q4 		$33K Hold
304
– – 0.02% 594
2019
Q3 		$30K Buy
304
+104
+52% +$11.7K 0.02% 607
2019
Q2 		$26K Hold
200
– – 0.01% 626
2019
Q1 		$27K Buy
+200
New +$24.9K 0.01% 610

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Investors Research Corp's ALXN Position: Q3 2021 in Review

Investors Research Corp sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 304 shares — an estimated $56K sold.

Investors Research Corp first reported a position in ALXN in Q1 2019 and held it in 10 quarters. The position peaked at $56K in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Investors Research Corp reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Investors Research Corp sold 304 Alexion Pharmaceuticals shares in Q3 2021, an estimated $56K.
  • Investors Research Corp first reported a position in Alexion Pharmaceuticals in Q1 2019 and held it in 10 quarters.
  • Investors Research Corp's Alexion Pharmaceuticals position peaked at $56K in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Investors Research Corp's 13F filing for Q3 2021, filed 27 Oct 2021.